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Abstract
Background: Although seasonal influenza vaccine is effective in the elderly, immune responses to vaccination are 
lower in the elderly than in younger adults. Strategies to optimise responses to vaccination in the elderly include using 
an adjuvanted vaccine or using an intradermal vaccination route. The immunogenicity of an intradermal seasonal 
influenza vaccine was compared with that of an adjuvanted vaccine in the elderly.
Methods: Elderly volunteers (age ≥ 65 years) were randomised to receive a single dose of trivalent seasonal influenza 
vaccine: either a split-virion vaccine containing 15 μg haemagglutinin [HA]/strain/0.1-ml dose administered 
intradermally, or a subunit vaccine (15 μg HA/strain/0.5-ml dose) adjuvanted with MF59C.1 and administered 
intramuscularly. Blood samples were taken before and 21 ± 3 days post-vaccination. Anti-HA antibody titres were 
assessed using haemagglutination inhibition (HI) and single radial haemolysis (SRH) methods. We aimed to show that 
the intradermal vaccine was non-inferior to the adjuvanted vaccine.
Results: A total of 795 participants were enrolled (intradermal vaccine n = 398; adjuvanted vaccine n = 397). Non-
inferiority of the intradermal vaccine was demonstrated for the A/H1N1 and B strains, but not for the A/H3N2 strain 
(upper bound of the 95% CI = 1.53) using the HI method, and for all three strains by the SRH method. A post-hoc 
analysis of covariance to adjust for baseline antibody titres demonstrated the non-inferiority of the intradermal vaccine 
by HI and SRH methods for all three strains. Both vaccines were, in general, well tolerated; the incidence of injection-site 
reactions was higher for the intradermal (70.1%) than the adjuvanted vaccine (33.8%) but these reactions were mild 
and of short duration.
Conclusions: The immunogenicity and safety of the intradermal seasonal influenza vaccine in the elderly was 
comparable with that of the adjuvanted vaccine. Intradermal vaccination to target the immune properties of the skin 
appears to be an appropriate strategy to address the challenge of declining immune responses in the elderly.
Trial registration: ClinicalTrials.gov: NCT00554333.
Background
The influenza A and B viruses are common respiratory
pathogens, with estimated annual global attack rates of 5-
10% in adults and 20-30% in children [1]. Seasonal influ-
enza can be a severe disease. It has been estimated that in
Europe between 40,000 and 220,000 excess deaths per
year can be attributed to influenza, depending on the
pathogenicity of the circulating virus [2]. Seasonal influ-
enza affects all age groups, but the highest incidence of
influenza-associated morbidity and mortality is seen in
children aged 0-23 months and in adults over 65 years of
age [3]. In the USA, influenza-associated deaths range
between 30 and 150 per 100,000 individuals aged over 65
years [1], and it is estimated that ~90% of deaths due to
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seasonal influenza occur among people aged ≥ 65 years
[1,4,5].
Annual vaccination continues to be the primary pre-
ventive measure against seasonal influenza. The World
Health Organization (WHO) recommends vaccination of
people at high risk of severe influenza or associated com-
plications, including elderly people [1]. The seasonal
influenza vaccine has been shown to be effective in
reducing influenza-like illness confirmed by laboratory
tests and influenza-associated morbidity and mortality in
high-risk groups [6-8]. However, the immune response to
the vaccine is lower in the elderly than in younger healthy
adults [9], due to a decline in immune function with age
('immunosenescence') [10].
To compensate for the effects of immunosenescence,
vaccines for elderly people must be adapted to optimise
the immune responses to vaccination. Several approaches
have been investigated, including use of an adjuvant
[11,12], increasing the doses of antigens (e.g. 60 μg hae-
magglutinin [HA] of each component compared with the
standard 15-μg dose) [13,14], and using new routes of
administration. Several studies have looked at ways to
improve immune responses to vaccination by delivering
vaccine via the intradermal route rather than the intra-
muscular or subcutaneous routes [15,16]. The dermis has
several unique properties that allow generation of power-
ful immune responses. In particular, it contains resident
and blood-derived dendritic cells. These have an impor-
tant role in the capture and presentation of antigens to
the cells of the adaptive immune system; it also has a rich
supply of blood and lymphatic vessels, allowing circula-
tion of immune cells [15,16]. Studies with vaccines
against a number of diseases such as hepatitis B and
rabies have demonstrated that intradermal delivery can
be an effective alternative route for vaccination [16].
Intanza® 15 μg (also known in some countries as IDflu®
15 μg) is the first intradermal influenza vaccine to be
licensed for use in elderly people (>60 years of age); it
received marketing authorisation in the European Union
in 2009 for use in adults 60 years of age or older. Consis-
tent with the WHO recommendations for seasonal influ-
enza vaccines, it contains each of one A/H1N1 strain, one
A/H3N2 strain, and one B strain [17]. Clinical studies in
elderly people have shown that Intanza 15 μg is more
immunogenic than the standard intramuscular vaccine
[18,19].
The present study was the first to compare the immu-
nogenicity of this intradermal vaccine with that of a
licensed adjuvanted influenza vaccine that was also
developed to increase immune responses in the elderly
[20]. The primary objective of the study was to demon-
strate that Intanza 15 μg is at least as immunogenic for
the three virus strains as the adjuvanted influenza vaccine
delivered via the intramuscular route in elderly volun-
teers.
Methods
Ethical approval of the study protocol
The study was approved by ethics committees in partici-
pating countries (Comité de Protection des Personnes,
France; Ethics Committee of Universitair Ziekenhuis
Antwerpen, Belgium), and also by the French Health
Products Safety Agency (Agence Française de Sécurité
Sanitaire des Produits de Santé, AFSSaPS) in France and
by the Federal Agency for Medicines and Health Products
(Federaal Agentschap voor Geneesmiddelen en Gezond-
heidsproducten, FAGG) in Belgium. The study was con-
ducted in accordance with the Declaration of Helsinki
and Good Clinical Practice. Participants gave written
informed consent before enrolment. The study was regis-
tered on ClinicalTrials.gov; identifier: NCT00554333.
Study design
This phase-III, multicentre, randomised, controlled,
open-label, parallel-group study was carried out in adults
aged 65 years or older who were recruited at three centres
in Belgium and seven centres in France between October
and December 2007. Participants attended the study cen-
tre on two occasions. At visit 1, participants who were eli-
gible for inclusion were randomised to receive
intradermal vaccine or an adjuvanted intramuscular
influenza vaccine. Investigators were provided with a
masked randomised list generated using a 1:1 ratio based
on balanced permuted blocks stratified by centre. A pre-
vaccination blood sample was taken and a single dose of
allocated vaccine given. At visit 2, which was scheduled
21 ± 3 days post-vaccination, a second blood sample was
taken for assessment of immunogenicity and collection of
vaccine safety data.
Participants
Individuals were invited to participate by the investiga-
tors via a phone call, an invitation letter, or during a con-
sultation. Participants aged 65 years or older were eligible
for enrolment in the study provided they met none of the
exclusion criteria: acute febrile illness (oral temperature ≥
37.5°C); systemic hypersensitivity to egg or chicken pro-
teins or any of the vaccine constituents; thrombocytope-
nia or a bleeding disorder contraindicating intramuscular
vaccination; and unstable chronic illness (defined as ill-
ness requiring hospitalisation or a clinically significant
change in medication in the previous 12 weeks). Individ-
u a l s  w e r e  a l s o  e x c l u d e d  i f  t h e y  h a d :  c o n g e n i t a l  o r
acquired immunodeficiency; received treatment with
immunosuppressive therapy within the previous 6
months or long-term treatment with systemic corticos-
teroids; received blood or blood-derived products in theVan Damme et al. BMC Infectious Diseases 2010, 10:134
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previous 3 months. Additional exclusion criteria were:
current abuse of alcohol or drug addiction; any vaccina-
tion within the previous 4 weeks or planned vaccination
within the 4 weeks after the first vaccination; seasonal
influenza vaccination in the previous 6 months; or previ-
ous seasonal influenza vaccination by the intradermal
route.
Vaccines
Both vaccines were formulated according to the WHO
recommendations for the 2007-2008 Northern Hemi-
sphere influenza season: A/Solomon Islands/3/2006
(H1N1)-like strain; A/Wisconsin/67/2005 (H3N2)-like
strain; and B/Malaysia/2506/2004-like strain.
The intradermal vaccine (Intanza® 15 μg; Sanofi Pasteur,
Lyon, France) is an inactivated, split-virion influenza vac-
cine containing 15 μg HA/strain per 0.1-ml dose, all
propagated in fertilised hen's eggs. The manufacturing
process is based on that used for the intramuscular sea-
sonal vaccine, with an additional concentration step to
obtain a lower volume for intradermal use. The vaccine
was administered in the deltoid region using a pre-filled
intradermal micro-needle injection system (Becton Dick-
inson; Franklin Lakes, NJ, USA) [21].
The adjuvanted vaccine (Addigrip®/Fluad®, Novartis
Vaccines and Diagnostics S.r.l., Origgio, Italy) is a subunit
(HA and neuraminidase) influenza vaccine containing 15
μg HA/strain per 0.5-ml dose, all propagated in fertilised
hen's eggs and adjuvanted with the squalene-based adju-
vant MF59C.1. The vaccine was administered by injec-
tion into the deltoid muscle.
Immunogenicity assessment
Consistent with previous studies of this intradermal vac-
cine, the primary immunogenicity endpoints were anti-
HA antibody titres (geometric mean titre) for the three
strains on day 21 post-vaccination [18,19]. Antibody
titres were determined for each strain before and 21 days
after vaccination by haemagglutination inhibition (HI)
assay [22]. This was carried out in accordance with stan-
dard procedures at sanofi pasteur in which the antibody
titre is the highest reciprocal dilution that induced com-
plete inhibition of haemagglutination (1/dilution [1/dil]).
The secondary endpoints were anti-HA antibody titres
for the three strains assessed using the single radial hae-
molysis (SRH) method, in which anti-HA antibody titres
are measured in square millimetres (mm2) [23]. SRH
assays were performed by the National Institute for Bio-
logical Standards and Control (NIBSC, Hertfordshire,
UK). HI and SRH assays are recognised by the European
Medicines Agency (EMA) for the assessment of the
immunogenicity of influenza vaccines [24,25].
The other secondary endpoints were anti-HA individ-
ual titre ratios (geometric mean titre ratio [GMTR], day
21/day 0) determined using the HI and SRH methods, the
post-vaccination seroprotection rate (defined as the per-
centage of patients with anti-HA titre ≥ 40 [1/dil] or ≥ 25
mm2 for the HI and SRH methods, respectively), and
seroconversion or significant increase rate on day 21
according to HI and SRH methods. For the HI method,
seroconversion was defined as post-vaccination anti-HA
titre ≥ 40 (1/dil) for subjects with a pre-vaccination titre <
10 (1/dil) and a significant increase was defined as ≥ four-
fold increase in anti-HA titre for subjects with a pre-vac-
cination titre ≥ 10 (1/dil). For the SRH method,
seroconversion was defined as a post-vaccination anti-
HA titre ≥ 25 mm2 for subjects with a pre-vaccination
titre ≤ 4 mm2, and a significant increase was defined as ≥
1.5-fold increase from pre-to post-vaccination for sub-
jects with a pre-vaccination titre > 4 mm2 [24].
Compliance with EMA criteria (as defined for annual
re-licensure trials) for the immunogenicity of influenza
vaccines in elderly people for both the HI and SRH meth-
ods was also assessed: a GMTR >2, a seroprotection rate
≥ 60%, and a rate of seroconversion or significant titre
increase ≥ 30% using either test [24].
Safety assessments
Participants used diary cards to record details of solicited
injection-site reactions (pain, erythema, swelling, indura-
tion, ecchymosis, pruritus) and solicited systemic reac-
tions (fever [rectal equivalent temperature ≥ 38.0°C],
headache, malaise, myalgia, shivering) occurring within 7
days of vaccination. Participants also recorded unsolic-
ited adverse events and serious adverse events occurring
within 21 days of vaccination. If the investigators felt that
adverse events were possibly, probably or definitely
related to the study vaccine, they were considered to be
'adverse reactions'. Occurrence of solicited adverse reac-
tions according to EMA criteria was also assessed in the
three days after vaccination: injection-site induration >5
cm observed for > 3 consecutive days; injection-site
ecchymosis; pyrexia (rectal equivalent temperature >
38.0°C) for ≥ 24 hours; malaise; and shivering [24].
Statistical methods
Three sets of participants were defined for the assess-
ment of immunogenicity, and one set for the safety analy-
sis (Table 1).
The primary hypothesis was that the immunogenicity
of the intradermal vaccine would be non-inferior to that
of the adjuvanted vaccine for each virus strain in terms of
antibody titres using the HI method. In the study, non-
inferiority was tested with HI and SRH methods, and was
defined as the upper bound of the 95% confidence inter-
vals (CIs) around the post-vaccination ratios of geometric
mean titres (GMT) (adjuvanted vaccine/intradermal vac-Van Damme et al. BMC Infectious Diseases 2010, 10:134
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cine) being < 1.5 for all three strains in the per protocol
set [26].
If non-inferiority was achieved for the three strains, the
superiority of the intradermal vaccine in the full analysis
set was also investigated. Superiority was defined as the
upper bound of the 95% CI being < 1 for at least two of
the three strains. The primary analysis model did not
include adjustments. Baseline antibody titres between the
two vaccine groups were different so, to improve the
accuracy of the estimates, a post-hoc analysis of covari-
ance (ANCOVA model with group and pre-vaccination
titre; no interaction) was performed to compare post-vac-
cination results adjusted according to pre-vaccination
levels [26].
To demonstrate non-inferiority of immune responses
induced by the intradermal vaccine compared with the
adjuvanted vaccine with a power of >90% and to allow for
10% of participants not being evaluable, enrolment of 395
participants was planned for each group to provide 355
evaluable participants per group in the per protocol anal-
ysis. The analysis of the secondary endpoints included
calculation of differences or ratios (and 95% CI) between
groups, and safety endpoints were analysed using
descriptive statistics.
Results
Participants
A total of 795 participants were enrolled in the study
(intradermal vaccine, n = 398; adjuvanted vaccine, n =
397; Table 1). Two participants withdrew from the study.
One participant in the intradermal vaccine group had a
cardiac arrest that led to death on day 20 (this event was
considered to be unrelated to the vaccine; this 82-year old
male had a history of coronary insufficiency and chronic
obstructive pulmonary obstruction and several risk fac-
tors for myocardial infarction, including hypertension
and past smoking). One participant in the adjuvanted
vaccine group withdrew consent. After the second study
visit, blood samples for analysis of immunogenicity were
available for 395 participants in each group. All sera were
Table 1: Description of analysis sets and numbers (percentage) of subjects by vaccine group; subjects were analysed 
according to the vaccine they received except for the randomised set
Intradermal vaccine, n (%) Adjuvanted vaccine, n (%)
Randomised seta 398 (100) 397 (100)
Full analysis setb 395 (99.2) 395 (99.5)
Per protocol setc
HI methodd 390 (98.0) 385 (97.0)
SRH methode 389 (97.7) 382 (96.2)
Other immunogenicity analysis set for EMA immunogenicity criteria f
HI method (full analysis set)
A/H1N1 395 (99.2) 395 (99.5)
A/H3N2 395 (99.2) 395 (99.5)
B 395 (99.2) 395 (99.5)
SRH methodg
A/H1N1 391 (98.2) 389 (98.0)
A/H3N2 391 (98.2) 388 (97.7)
B 391 (98.2) 389 (98.0)
Safety seth 398 (100) 397 (100)
a All individuals randomised who received a study vaccine.
b All randomised individuals who received a study vaccine and who had post-vaccination immunogenicity results. Intradermal vaccine group: 
one participant withdrew due to a serious adverse event, and insufficient blood samples for testing were noted for two participants; 
adjuvanted vaccine group: one participant withdrew consent and an insufficient blood sample for testing was noted for one participant.
c All randomised individuals except those with protocol violations that could interfere with the immunogenicity evaluation.
d Additional participants with at least one protocol deviation excluded: intradermal vaccine group n = 5, adjuvanted vaccine group n = 10.
e Additional excluded participants with insufficient blood samples: intradermal vaccine group n = 1, adjuvanted vaccine group n = 3.
f Participants who received a study vaccine and for whom pre-and post-vaccination titres on days 0 and 21 were available for each strain.
g Additional participants excluded because of missing pre-and/or post-vaccination SRH method results: intrademal vaccine group n = 4 for 
all three strains; adjuvanted vaccine group n = 6 for A/H1N1 and B and n = 7 for A/H3N2.
h Participants who received a study vaccine and who had post-vaccination safety data.Van Damme et al. BMC Infectious Diseases 2010, 10:134
http://www.biomedcentral.com/1471-2334/10/134
Page 5 of 11
tested by the HI method and most of them (with ade-
quate samples) were evaluated by the SRH method (Table
1).
The demographic characteristics of the participants
randomised in the two groups were comparable (Table 2).
The study involved 370 men (46.5%) and 425 women
(53.5%), with a mean age of 74.3 ± 6.4 years (range, 60.3-
94.2 years). One individual aged 60.3 years and who was
therefore below the age for inclusion was randomised by
error and received the intradermal vaccine. This individ-
ual was excluded from the per protocol analyses but
included in all other analyses. Most participants in both
groups (89.9%) had past and/or current significant medi-
cal conditions, but only 52.7% of participants had under-
l y i n g  d i s e a s e s  i d e n t i f i e d  a s  r i s k  f a c t o r s  f o r  i n f l u e n z a -
related morbidity (mainly heart diseases). Overall, 72.5%
of participants had been vaccinated against influenza in
the previous season (2006-2007).
Immunogenicity
The geometric mean antibody titres induced by the intra-
dermal and adjuvanted vaccines for all three virus strains
by both the HI and SRH methods are summarised in
Table 3. For the primary objective of non-inferiority of
the intradermal vaccine immunogenicity compared with
that for the adjuvanted vaccine assessed by the HI
method in the per protocol population, non-inferiority
was not demonstrated for the A/H3N2 strain (upper
bound of the 95% CI = 1.53) (Table 3). Non-inferiority
was demonstrated for all three strains by the SRH
method (Table 3). Similar results for the three strains
were observed in the full analysis set with both the HI and
the SRH methods (ratios [adjuvanted vaccine/intrader-
mal vaccine] of post-vaccination GMT: A/H1N1 1.12, A/
H2N3 1.31, B 1.07; and A/H1N1 1.16, A/H2N3 1.18, B
1.05, respectively). Non-inferiority of the intradermal
vaccine was not demonstrated for all three strains by the
HI method, so the superiority of the vaccine was not
tested. Superiority of the intradermal vaccine by the SRH
method was tested on the full analysis set, but superior
immunogenicity was not demonstrated for any of the
virus strains.
For the A/H1N1 strain (HI method), baseline and post-
vaccination antibody titres were correlated (Pearson's
correlation coefficient ρ = 0.5 in per protocol set) and
baseline antibody titres were slightly different in the two
groups (pre-vaccination GMTR of 1.15 in per protocol
set). Therefore a post-hoc ANCOVA adjusting for base-
line values was carried out. Non-inferiority of the intrad-
ermal vaccine compared with the adjuvanted vaccine for
all three virus strains by HI and SRH methods was
observed (Table 4).
In the immunogenicity assessment by the HI method,
the results for the A/H1N1 and A/H3N2 strains with
both vaccines satisfied all three EMA criteria, and the
results for the B strain with both vaccines satisfied the
EMA criterion for GMTR (Figure 1). When immunoge-
nicity was assessed by the SRH method, the results for all
three strains with both vaccines satisfied all EMA immu-
nogenicity criteria (Figure 1). There were no significant
Table 2: Demographic data and baseline characteristics (randomised set)
Total Intradermal vaccine Adjuvanted vaccine
N = 795 N = 398 N = 397
Mean age (years; SD) 74.3 (6.4) 73.9 (6.3) 74.7 (6.6)
- over 75 (n; %) 329 (41.4) 154 (38.7) 175 (44.1)
Males (n; %) 370 (46.5) 194 (48.7) 176 (44.3)
Mean body mass index (kg/m2; SD) 27.1 (4.5) 27.0 (4.5) 27.2 (4.5)
Past or current significant medical history (n; %) 715 (89.9) 358 (89.9) 357 (89.9)
- risk factor a (n; %) 419 (52.7) 216 (54.3) 203 (51.1)
- history of allergy b (n; %) 67 (8.4) 29 (7.3) 38 (9.6)
Last influenza vaccination c
- previous season 2006-2007 (n; %) 576 (72.5) 287 (72.1) 289 (72.8)
- prior to previous season (n; %) 57 (7.2) 26 (6.5) 31 (7.8)
Percentages are based on the number of randomised subjects having available data
a At least one of the following: lung disease, heart disease, diabetes, renal disease, neurological abnormality or other significant medical 
history such as HIV, cancer, hepatitis (A, B, C), epilepsy, auto-immune diseases or blood disorders reported during the medical history review
b At least one allergic condition reported as medical history
c Percentages are calculated based on the number of randomised subjects who had previously been vaccinated against influenza and who 
had available data. 7 subjects (4 from the intradermal vaccine group and 3 from the adjuvanted vaccine group) had previously been 
vaccinated against influenza by the intradermal routeVan Damme et al. BMC Infectious Diseases 2010, 10:134
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differences between the two vaccine groups in GMTRs,
seroprotection rates, and seroconversion/significant
increase rates for the three virus strains by either assay,
with the exception of the seroprotection rate for the A/
H1N1 strain (Figure 1). Although the seroprotection rates
for the A/H1N1 strain were high in both the intradermal
and adjuvanted groups (HI method: 81.3% and 87.1%,
respectively; SRH method: 84.3% and 90.1%, respec-
tively), they were higher in the adjuvanted vaccine group
(difference between groups: HI method: 5.8% [95% CI:
0.7-10.9]; SRH method: 5.8% [95% CI: 1.1-10.5]).
Safety
The incidence of reactions within three days after the first
vaccination listed in the EMA guideline (most commonly
shivering and malaise) was similar in the intradermal and
adjuvanted vaccine groups (Table 5). Induration of >5 cm
that lasted for >3 days was not observed in either group.
More participants in the intradermal vaccine group
reported at least one solicited injection-site reaction
(70.1%) compared with the adjuvanted vaccine group
(33.8%). Erythema was reported more frequently in the
intradermal vaccine group (63.1% vs. 13.4%). Swelling
(34.2% vs. 8.6%), induration (32.9% vs. 10.6%) and pruri-
tus (28.1% vs 6.5%) were also more frequently reported
Table 3: Post-vaccination geometric mean titres (GMT) and ratios of GMT (adjuvanted vaccine/intradermal vaccine) for the 
three virus strains on day 21 in the per protocol set assessed by the haemagglutinin inhibition (HI) and single radial 
haemolysis (SRH) methods
HI method (1/dil) SRH method (mm2)
Intradermal 
vaccine
(N = 390)
Adjuvanted 
vaccine
(N = 385)
Intradermal 
vaccine
(N = 389)
Adjuvanted 
vaccine
(N = 382)
Virus strain Pre or 
Post 
vaccination
GMT
[95% CI]
Ratios of GMT
[95% CI]
GMT [95% CI] Ratios of GMT
[95% CI]
A/H1N1 Pre- 13.3 [12.1;14.6] 13.5 [12.3;14.9] -- 7.7 [6.9;8.6] 8.0 [7.2;8.9] --
Post- 108.3 [95.4;123.0] 122.1 [109.1;136.7] 1.13 [0.95;1.34]* 46.4 [41.6;51.8] 53.9 [49.0;59.3] 1.16 [1.00;1.34]*
A/H3N2 Pre- 60.3 [52.2;69.7] 69.4 [59.5;81.0] -- 11.0 [9.8;12.5] 12.7 [11.2;14.3] --
Post- 259.9 [233.5;289.3] 341.4 [306.7;380.1] 1.31 [1.13;1.53] 39.3 [35.6;43.3] 46.2 [42.1;50.7] 1.18 [1.03;1.34]*
B Pre- 15.0 [13.7;16.4] 16.5 [15.1;18.1] -- 29.2 [25.6;33.2] 28.0 [24.5;32.1) --
Post- 36.9 [33.6;40.5] 39.9 [36.4;43.8] 1.08 [0.95;1.23]* 66.5 [60.8;72.8] 68.9 [62.9;75.3] 1.03 [0.91;1.17]*
*Non-inferiority of the intradermal vaccine was demonstrated if the upper bound of the 95% CI for the ratios of GMT was < 1.5.
Table 4: Post-hoc analysis in which post-vaccination geometric mean titres (GMTs) were adjusted according to pre-
vaccination titres and ratios of GMT (adjuvanted vaccine/intradermal vaccine) for the three virus strains on day 21 in the 
per protocol set assessed by haemagglutinin inhibition (HI) and single radial haemolysis (SRH) methods
HI method (1/dil) SRH method (mm2)
Intradermal 
vaccine
(N = 390)
Adjuvanted 
vaccine
(N = 385)
Intraderma
l vaccine
(N = 389)
Adjuvante
d vaccine
(N = 382)
Virus strain Post-vaccination GMT
[95% CI]
Ratios of GMT
[95% CI]
Post-vaccination GMT
[95% CI]
Ratios of GMT
[95% CI]
A/H1N1 108.8 121.6 1.12 47.1 54.0 1.15
[97.4;121.5] [108.8;135.9] [0.95;1.31]* [42.8;51.9] [49.0;59.6] [1.00;1.32]*
A/H3N2 266.5 332.8 1.25 40.3 45.3 1.12
[243.1;292.3] [303.3;365.2] [1.10;1.42]* [37.0;44.0] [41.5;49.4] [0.99;1.27]*
B 37.9 38.9 1.03 65.8 69.8 1.06
[35.0;41.0] [35.9;42.1] [0.92;1.15]* [61.0;71.1] [64.6;75.4] [0.95;1.18]*
* Non-inferiority of the ID vaccine was demonstrated if the upper bound of the 95% CI for the ratios of GMT was < 1.5Van Damme et al. BMC Infectious Diseases 2010, 10:134
http://www.biomedcentral.com/1471-2334/10/134
Page 7 of 11
Figure 1 Comparison of European Medicines Agency (EMA) immunogenicity variables for the intradermal and adjuvanted influenza vac-
cines assessed by haemagglutinin inhibition (HI; left-hand column) and single radial haemolysis (SRH; right-hand column) methods. Anal-
yses were carried out with the other immunogenicity analysis set (participants who received a study vaccine and for whom pre-and post-vaccination 
titres on days 0 and 21 were available for each strain). The horizontal line indicates the EMA threshold for each variable. (a) Ratio of individual post-and 
pre-vaccination geometric mean titres (GMTR); (b) Post-vaccination seroprotection rate1 (%); (c) Seroconversion/significant increase rate2 (%).
*: statistically significantly difference between the groups (adjuvanted vaccine -intradermal vaccine) was observed for the A/Solomon (HINI) strain us-
ing the full analysis set: 5.8% (95% CI: 1.1-10.5).
1Seroprotection: percentage of participants with anti-HA titre ≥ 40 [1/dil] or ≥ 25 mm2 for HI and SRH methods, respectively.
2Seroconversion: anti-HA post-vaccination titre ≥ 40 (1/dil; HI method) or ≥ 25 mm2 (SRH method) for participants with a pre-vaccination anti-HA in-
dividual titre < 10 (1/dil; HI method) or ≥ 4 mm2 (SRH method). Significant increase: ≥ fourfold increase (HI method) or ≥ 1.5-fold increase (SRH method) 
from pre-to post-vaccination anti-HA individual titre for participants with a pre-vaccination anti-HA individual titre ≥ 10 (1/dil - HI method) or > 4 mm2 
(SRH method).Van Damme et al. BMC Infectious Diseases 2010, 10:134
http://www.biomedcentral.com/1471-2334/10/134
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but at a lower incidence than for erythema. The propor-
tion of participants who reported pain (19.8% vs. 20.9%)
or ecchymosis (4.8% vs. 3.0%) was comparable between
the two vaccine groups (Figure 2a). Most of the solicited
injection-site reactions were of mild intensity or < 2.5 cm,
and most occurred between day 0 and day 3 post-vacci-
nation and lasted ≤ 3 days without treatment. Injection-
site erythema lasted ≥ 8 days in 22 participants in the
intradermal vaccine group compared with 4 participants
in the adjuvanted vaccine group.
Overall, 99 participants (24.9%) in the intradermal vac-
cine group and 96 participants (24.2%) in the adjuvanted
vaccine group reported at least one solicited systemic
reaction in the first 7 days after vaccination. The inci-
dence of each solicited systemic reaction was comparable
for the two vaccine groups (Figure 2b). Most reactions
were of mild intensity. Only 4.0% of the participants in
the intradermal vaccine group and 5.8% of those in the
adjuvanted vaccine group had a fever. In both groups
pyrexia was, in general, ≤ 38.5°C (3.3% and 4.0% of sub-
jects, respectively) and none were > 39.6°C, During the 21
days post-vaccination, there were no differences between
the intradermal and adjuvanted vaccine groups in the
proportion of participants reporting systemic adverse
events (31.9% vs 32.5%; severe 3.3% vs 2.5%) or systemic
adverse reactions (26.4% vs 25.9%; severe 2.0% vs 1.8%).
No unsolicited adverse events occurred within 30 min-
utes of vaccination in either group. Six participants
reported serious adverse events, two of which were con-
sidered by the investigator to be possibly related to vacci-
nation: a participant in the intradermal vaccine group
presented with pneumonia one day after vaccination, and
a participant in the adjuvanted vaccine group presented
with facial herpes zoster three days after vaccination.
Discussion
This study showed that, in elderly volunteers, the immu-
nogenicity of the intradermal seasonal influenza vaccine
is largely comparable with that of the adjuvanted influ-
enza vaccine. The two vaccines induced similar levels of
anti-HA antibodies as assessed by the SRH method. Non-
inferiority of the intradermal vaccine compared with the
adjuvanted vaccine was demonstrated for the A/H1N1
and B strains with the HI method and for all three strains
with the SRH method. Both vaccines satisfied the EMA
immunogenicity criteria for influenza vaccines in the
elderly. Both vaccines were developed to address the chal-
lenge of immunosenescence. The aim of the adjuvant in
the seasonal influenza vaccine is to increase the immuno-
genicity in elderly people [20], whereas this intradermal
vaccine reaches the same goal by reliably delivering the
vaccine into the rich immune environment of the dermis
a using a micro-needle injection system [15,16,21].
The HI assay is the most widely used for surveillance of
the influenza virus and for assessing responses to vac-
cines in clinical trials [25]. The HI and SRH methods pro-
vide serological correlates of protection [25], and are
recognised by the EMA for the evaluation of influenza
Table 5: Incidence of solicited adverse reactions as defined by the EMA in the first three days after vaccination
Intradermal vaccine Adjuvanted vaccine
(N = 398) (N = 397)
nn
(%; [95% CI]) (%; [95% CI])
≥ 1 adverse reaction 51 55
(12.8 [9.7;16.5]) (13.9 [10.6;17.6])
Injection-site indurationa 0 0
(0 [0.0;0.9]) (0 [0.0;0.9])
Injection-site ecchymosis 13 12
(3.3 [1.8;5.5]) (3.0 [1.6;5.2])
Pyrexiab 61 2
(1.5 [0.6;3.3]) (3.0 [1.6;5.2])
Malaise 19 20
(4.8 [2.9;7.4]) (5.0 [3.1;7.7])
Shivering 24 23
(6.0 [3.9;8.8]) (5.8 [3.7;8.6])
a > 5 cm for > 3 consecutive days.
b Rectal equivalent temperature > 38.0°C for ≥ 24 hours.Van Damme et al. BMC Infectious Diseases 2010, 10:134
http://www.biomedcentral.com/1471-2334/10/134
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vaccines [24]. The good agreement between the results
from the HI and SRH tests for the A strains reported pre-
viously [27] was also observed in the present study
because the results from both tests were comparable for
the A strains for both vaccines. Results from the SRH
assay satisfied all three EMA immunogenicity criteria for
both vaccines, whereas the HI assay results satisfied only
the GMTR criterion, confirming the higher sensitivity of
the SRH assay for influenza B strains [25,27].
Due to the epidemiology of influenza and vaccination
programmes in industrialised countries, few elderly peo-
ple are seronegative to circulating seasonal influenza
antigens [26]. Beyer et al. demonstrated that pre-vaccina-
tion antibody titres can have an important influence on
the results of immunogenicity studies with influenza vac-
cines (e.g. underestimation of antibody responses) [28].
They proposed that post-vaccination results should be
adjusted according to individual pre-vaccination titres so
as to provide a more informative measure of serological
responses to influenza vaccines [28]. In the present study,
baseline GMTs for all strains (but particularly the A/
H3N2 strain) were slightly lower in the intradermal vac-
cine group than in the adjuvanted vaccine group.
Although the A/H3N2 strain failed to meet the criterion
for non-inferiority when assessed by the HI method in
the primary analysis, the post-hoc covariance analysis to
adjust for pre-vaccination anti-HA titres demonstrated
that the intradermal vaccine was non-inferior to the adju-
vanted vaccine for all three virus strains assessed by the
HI method.
In general, the intradermal and adjuvanted vaccines
were well tolerated, with comparable proportions of par-
ticipants reporting solicited systemic reactions in the two
groups. The two vaccines were also comparable accord-
Figure 2 Summary of safety assessments with the intradermal and adjuvanted vaccines on days 0-7 post-vaccination. (a) Incidence of all and 
of severe solicited injection-site reactions. (b) Incidence of solicited systemic reactionsVan Damme et al. BMC Infectious Diseases 2010, 10:134
http://www.biomedcentral.com/1471-2334/10/134
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ing to the EMA criteria for the safety of influenza vac-
cines. The micro-needle injection system used to deliver
Intanza 15 μg has advantages over the adjuvanted vaccine
from the perspective of local safety. The needle pene-
trates only 1.5 mm into the skin, so the risk of damage to
nerves or veins inherent with intramuscular injection is
eliminated [19,21]. The increased rate of injection-site
erythema compared with intramuscular vaccination has
been reported in studies with this intradermal vaccine in
elderly volunteers [18,19]. The injection of vaccine just
below the skin surface means that local reactions are
more readily and more frequently visible than after injec-
tion of vaccine deeper into the muscle even if the symp-
toms ere mainly mild and of short duration[16,29,30].
Importantly, injection-site reactions in the intradermal
g r o u p  w e r e  n o t  a s s o c i a t e d  w i t h  a  h i g h e r  i n c i d e n c e  o r
severity of injection-site pain, and most reactions lasted
for ≤ 3 days.
Conclusion
The present study demonstrated that the immunogenic-
ity and safety of a new intradermal seasonal influenza
vaccine for use in the elderly, Intanza 15 μg, is largely
comparable with that of the adjuvanted vaccine that has
been licensed for use in elderly people in Europe for sev-
eral years. Thus, intradermal vaccination to target the
immune properties of the skin appears to be an appropri-
ate strategy to address the challenge of declining immune
responses in the elderly.
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